With the completion of the 450 million yuan B round of financing, Boya will continue to promote the clinical transformation of gene editing technology.

Arterial Network was first informed that Beijing, China and Cambridge, Massachusetts, USA, October 13, 2020, Boya, based on genome editing technology, for a variety of diseases to accelerate drug research and development of innovative therapies biopharmaceutical enterprises, announced the successful completion of 450 million yuan B round of financing.
This round of financing by Sanzheng Health Investment Lead Investment, Sequoia Capital China Fund, Yahui Investment, Kunlun Capital and Investment, the company's existing investors IDG Capital, Lilly Asia Fund, Huagai Capital, Songyu Capital and Investment, continue to support the company's development.
this round of financing will be used to advance the clinical transformation of the research and development pipeline and further expand the team.
, a revolutionary technology in the field of life medicine, is advancing clinically at a rapid rate around the world," said Dr. Wang Yuchuan, investment partner at Sanzheng Health.
is a pioneer in the field of gene editing in China, not only has the leading clinical transformation and industrialization strength, but also has editing tools and the original research and development capabilities of the underlying core technology.
we are proud to lead this B-round of financing, working with our corporate team and new and existing investors to bring life-changing and innovative gene therapies to patients in China and around the world.
, we look forward to supporting the company's development in clinical transformation, industrial development, and policy, and helping Boya to become a leader in gene therapy.
the past two years, Boya has successfully completed a 700 million yuan financing.
We appreciate the addition and recognition of new investors and the continued support of the investors who have accompanied us from the early stages of the company's development," said Dr. Wei Dong, CEO of Boya, "The successful completion of this financing will support our business to scale up and transform into a clinical phase, which is an important step in building a globally competitive biopharmaceutical company in the field of gene editing, and, more importantly, we are on track to achieve our vision of bringing innovative, high-quality therapies to patients as soon as possible."
"Thank you very much for your recognition and support, and for pushing the company into a new stage of development," said Dr. Wensheng Wei, founder of Boyaine Science.
" Boya, founded in 2015, now has four platforms centered on gene editing technology and is working to promote research and development projects for genetic diseases and tumors into the clinic.
's four platforms include in vitro cell gene editing therapy platform for hematopoietic stem cells and T-cells, in vivo gene editing therapy platform based on RNA single base editing technology, and high-volume genome editing and screening platform dedicated to targeted drug development.
, Boya has established a clinical conversion application base in Nansha District, Guangzhou, in 2018 that meets GMP standards.
about EdiGene, Inc. is a biopharmaceutical company dedicated to accelerating drug research and developing innovative therapies for a wide range of genetic diseases and cancers through international cutting-edge genomic editing technologies.
Boya has established an in vitro cell gene editing treatment platform with independent intellectual property rights for hematopoietic stem cells and T-cells, an in vivo gene therapy platform based on RNA single base editing technology, and a high-volume genome editing and screening platform dedicated to targeted drug development.
founded in 2015, the company is headquartered in Beijing and has offices in Guangzhou and Cambridge, USA.
about Sanzheng Health Investment Sanzheng Health Investment is a private equity fund focused on the healthcare industry.
we focus on clinically unsealed needs, investing in innovative medical and health technologies to drive their clinical transformation and industrialization, while saving more lives and improving the quality of patient life.
health investment relies on clinical, industrial, policy deep resources, and partners to create a great health technology enterprises.
about Sequoia Capital China Fund Sequoia Capital is always committed to helping entrepreneurs achieve the foundation of evergreen great companies, to bring member companies a wealth of global resources and valuable historical experience.
48 years, Sequoia Capital has invested in many innovative companies and industry trends.
Sequoia Capital China Fund is an "entrepreneur behind entrepreneurs" focused on investment opportunities in the four directions of technology/media, healthcare, consumer goods/modern services, and industrial technology.
15 years, Sequoia Capital China Fund has invested in nearly 600 companies with distinctive technical characteristics, innovative business models, high growth and high growth potential.
About Yahui Investment Yahui Investment is a professional fund focused on early investments in the life sciences.
we systematically lay out innovative drug development and breakthrough diagnostic technologies in the life sciences, driven by professional research, with scientific lines as clues.
committed to long-term investments in the life sciences, pursuing excess returns based on in-depth scientific understanding.
Investment was established in 2015, the core management team in the medical and pharmaceutical industry has a senior investment and research background.
has invested in more than 20 companies in the life sciences sector and has developed its own leaders in a number of segments.
About Kunlun Capital Kunlun Capital is an investment management agency focused on investment in scientific and technological innovation-oriented enterprises, founded in 2015 by Mr. Zhou Yahui, founder of Kunlun Wanwei, an A-share listed company, and Opera, a U.S.-listed company.
assets management is more than 10 billion yuan.
Kunlun Capital focuses on innovative business models driven by technology/product/data, and looks for entrepreneurial teams with global potential and localization capabilities through a selection of head companies in the sub-sectors.
investment cases include: Hei He Ningyuan, and Yuan Bio, Koya Medical, musical.ly, Dada, Look, pony ai, Pursuit, Le Yan, etc.
.